Aligos Therapeutics vs Marker Therapeutics
Marker Therapeutics is the larger business, with $3.5m of revenue in fiscal 2025 against $2.2m for Aligos Therapeutics (1.6 times as much). Aligos Therapeutics grew faster (-39.5% against -46.2%). Marker Therapeutics kept more of each dollar of sales as profit: a net margin of -343.0% against -1106.7%.
| Latest fiscal year | Aligos TherapeuticsALGS, 2025 | Marker TherapeuticsMRKR, 2025 |
|---|---|---|
| Revenue | $2.2m | $3.5m |
| Revenue growth | -39.5% | -46.2% |
| Net income | −$24.2m | −$12.2m |
| Operating margin | — | -363.5% |
| Net margin | -1106.7% | -343.0% |
| Return on equity | -196.9% | -68.8% |
| Free cash flow | −$82.5m | −$12.0m |
| Cash | $18.3m | $16.1m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 82 | 5 |
| Market value | $29.6m | $16.5m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |